The sphingosine-1-phosphate receptor 1 modulator ponesimod repairs cuprizone-induced demyelination and induces oligodendrocyte differentiation

被引:4
作者
Willems, Emily [1 ,2 ]
Schepers, Melissa [1 ,2 ,3 ]
Piccart, Elisabeth [1 ]
Wolfs, Esther [4 ]
Hellings, Niels [3 ,5 ]
Ait-Tihyaty, Maria [6 ]
Vanmierlo, Tim [1 ,2 ,3 ]
机构
[1] Hasselt Univ, Biomed Res Inst, Fac Med & Life Sci, Dept Neurosci, Diepenbeek, Belgium
[2] Maastricht Univ, Sch Mental Hlth & Neurosci, Dept Psychiat & Neuropsychol, Maastricht, Netherlands
[3] Univ MS Ctr UMSC Hasselt Pelt, Hasselt, Belgium
[4] Hasselt Univ, Biomed Res Inst BIOMED, Dept Cardio & Organ Syst, Diepenbeek, Belgium
[5] Hasselt Univ, Biomed Res Inst, Dept Immunol & Infect, Diepenbeek, Belgium
[6] Janssen Res & Dev LLC, Titusville, NJ USA
关键词
cuprizone; multiple sclerosis; oligodendrocyte precursor; remyelination; visual evoked potentials; MULTIPLE-SCLEROSIS; PROGENITOR CELLS; REMYELINATION; POPULATION; ATLAS;
D O I
10.1096/fj.202301557RR
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sphingosine-1-phosphate receptor (S1PR) modulators are clinically used to treat relapse-remitting multiple sclerosis (MS) and the early phase of progressive MS when inflammation still prevails. In the periphery, S1PR modulators prevent lymphocyte egress from lymph nodes, hence hampering neuroinflammation. Recent findings suggest a role for S1PR modulation in remyelination. As the Gi alpha-coupled S1P1 subtype is the most prominently expressed S1PR in oligodendrocyte precursor cells (OPCs), selective modulation (functional antagonism) of S1P1 may have direct effects on OPC functionality. We hypothesized that functional antagonism of S1P1 by ponesimod induces remyelination by boosting OPC differentiation. In the cuprizone mouse model of demyelination, we found ponesimod to decrease the latency time of visual evoked potentials compared to vehicle conditions, which is indicative of functional remyelination. In addition, the Y maze spontaneous alternations test revealed that ponesimod reversed cuprizone-induced working memory deficits. Myelin basic protein (MBP) immunohistochemistry and transmission electron microscopy of the corpus callosum revealed an increase in myelination upon ponesimod treatment. Moreover, treatment with ponesimod alone or in combination with A971432, an S1P5 monoselective modulator, significantly increased primary mouse OPC differentiation based on O4 immunocytochemistry. In conclusion, S1P1 functional antagonism by ponesimod increases remyelination in the cuprizone model of demyelination and significantly increases OPC differentiation in vitro. Ponesimod reverses a cuprizone-induced working memory deficit, restores the cuprizone-induced delay in latency time of the optic pathway, and enhances remyelination after cuprizone intoxication in vivo. Furthermore, ponesimod enhances differentiation of oligodendrocyte precursor cells into mature oligodendrocytes in vitro.image
引用
收藏
页数:15
相关论文
共 53 条
[1]   Siponimod: First Global Approval [J].
Al-Salama, Zaina T. .
DRUGS, 2019, 79 (09) :1009-1015
[2]   Fingolimod does not enhance cerebellar remyelination in the cuprizone model [J].
Alme, Maria Nordheim ;
Nystad, Agnes E. ;
Bo, Lars ;
Myhr, Kjell-Morten ;
Vedeler, Christian A. ;
Wergeland, Stig ;
Torkildsen, Oivind .
JOURNAL OF NEUROIMMUNOLOGY, 2015, 285 :180-186
[3]   Investigation into MAO B-Mediated Formation of CC112273, a Major Circulating Metabolite of Ozanimod, in Humans and Preclinical Species: Stereospecific Oxidative Deamination of (S)-Enantiomer of Indaneamine (RP101075) by MAO B [J].
Bai, April ;
Shanmugasundaram, Veerabahu ;
Selkirk, Julie, V ;
Surapaneni, Sekhar ;
Dalvie, Deepak .
DRUG METABOLISM AND DISPOSITION, 2021, 49 (08) :601-609
[4]   Siponimod and Cognition in Secondary Progressive Multiple Sclerosis EXPAND Secondary Analyses [J].
Benedict, Ralph H. B. ;
Tomic, Davorka ;
Cree, Bruce A. ;
Fox, Robert ;
Giovannoni, Gavin ;
Bar-Or, Amit ;
Gold, Ralf ;
Vermersch, Patrick ;
Pohlmann, Harald ;
Wright, Ian ;
Karlsson, Goril ;
Dahlke, Frank ;
Wolf, Christian ;
Kappos, Ludwig .
NEUROLOGY, 2021, 96 (03) :E376-E386
[5]   Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study [J].
Brossard, Patrick ;
Derendorf, Hartmut ;
Xu, Jian ;
Maatouk, Haidar ;
Halabi, Atef ;
Dingemanse, Jasper .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (06) :888-896
[6]   ATLAS OF MULTIPLE SCLEROSIS 2013: A GROWING GLOBAL PROBLEM WITH WIDESPREAD INEQUITY [J].
Browne, Paul ;
Chandraratna, Dhia ;
Angood, Ceri ;
Tremlett, Helen ;
Baker, Chris ;
Taylor, Bruce V. ;
Thompson, Alan J. .
NEUROLOGY, 2014, 83 (11) :1022-1024
[7]   FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors [J].
Chiba, K .
PHARMACOLOGY & THERAPEUTICS, 2005, 108 (03) :308-319
[8]   International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid Receptor Nomenclature [J].
Chun, Jerold ;
Hla, Timothy ;
Lynch, Kevin R. ;
Spiegel, Sarah ;
Moolenaar, Wouter H. .
PHARMACOLOGICAL REVIEWS, 2010, 62 (04) :579-587
[9]   Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial [J].
Comi, Giancarlo ;
Kappos, Ludwig ;
Selmaj, Krzysztof W. ;
Bar-Or, Arnit ;
Arnold, Douglas L. ;
Steinman, Lawrence ;
Hartung, Hans-Peter ;
Montalban, Xavier ;
Havrdova, Eva Kubota ;
Cree, Bruce A. C. ;
Sheffield, James K. ;
Minton, Neil ;
Raghupathi, Kartik ;
Ding, Ning ;
Cohen, Jeffrey A. .
LANCET NEUROLOGY, 2019, 18 (11) :1009-1020
[10]  
Coret Francisco, 2018, Mult Scler J Exp Transl Clin, V4, p2055217318783347, DOI [10.1177/2055217318783347, 10.1177/2055217318783347]